ArticleMolecular & cellular oncology2026
Exploration of the diagnostic and therapeutic potential of the nucleocytoplasmic shuttling protein TMUB1 by inducing G0/G1 cell cycle arrest in ovarian cancer.
Article in Molecular & cellular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer is one of the leading causes of gynaecologic malignancies worldwide. This study aimed to explore the diagnostic and therapeutic potential of TMUB1 in ovarian cancer. Methods: To investigate the subcellular localization of TMUB1 under serum deprivation conditions, immunofluorescence staining was performed. The cell cycle distribution was analysed by flow cytometry. TMUB1-interacting proteins were identified through immunoprecipitation followed by mass spectrometry. Kaplan-Meier survival analysis was used to compare overall survival between patients with high and low TMUB1 expression. Stromal and immune scores for tumour tissues in TCGA were calculated to assess the tumour microenvironment. Results: TMUB1 plays a crucial role in regulating the cell cycle by promoting entry into the G0/G1 phase. Survival analysis revealed that TMUB1 expression is positively associated with favourable prognosis in patients with ovarian cancer. Pathway enrichment analysis highlighted several tumour-related pathways, including ECM-receptor interaction, JAK-STAT signalling, p53 signalling and apoptosis. The high TMUB1 expression group presented lower stromal scores. An inverse correlation was observed between TMUB1 expression and the expression of key immune checkpoint proteins. Conclusions: TMUB1 might participate in the regulation of the G0/G1 cell cycle arrest, and it is a potential diagnostic marker and therapeutic target for ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.